2025 Industry Supported Session

Lunch 'n Learn 7: A Beacon of Light: Advancing Care in Rare Neurological Disorders

Tuesday, June 11, 2025 - 12:00 PM – 1:30 PM Eastern

Rogers Centre Ottawa, Level 2, Room 207

Faculty: Michael Nicolle • Vijay Ramaswamy • Michelle Mezei • Mark Freedman

---

Description:
Join us at the CNSF conference for a compelling lunch and learn symposium, focusing on Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Neurofibromatosis Type 1, and Hereditary Transthyretin Amyloidosis. Led by a panel of leading experts in each field, this session will explore the diagnostic and management strategies for these rare neurological disorders.

Learning Objectives:

- Examine recent long-term evidence and real-world experience of Complement-5 (C5) inhibitors in the management of Generalized Myasthenia Gravis (gMG)
- Understand the diagnosis and treatment options for NF1- associated PN (Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN)) for pediatric patients
- Enhance diagnostic and patient management strategies in ATTR Amyloidosis to improve overall patient outcomes
- Recognize the impact of novel biologic use in reducing relapse risk and improving patient outcomes in AQP4-positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Audience: Adult Neurologist, Child Neurologist, Neurosurgeon, Neurophysiologist, Resident, Fellow, Nurses with interest in topic
Learning Level: Basic (Resident, New Information), Intermediate (Practicing Physician), Advanced (Special Interest, Higher Level Discussion)
Learning Format: Audience response system, Case studies, Lecture/plenary method, Question and answer sessions
CanMEDs Roles: Medical Expert, Scholar, Collaborator, Leader, Health Advocate

Time	Presentation Title	Name of Speaker
12:00 PM ET	Introduction	Michael Nicolle
12:05 PM ET	gMG + Q&A	Michael Nicolle
12:25 PM ET	NF1 + Q&A	Vijay Ramaswamy
12:45 PM ET	ATTR Amyloidosis + Q&A	Michelle Mezei
1:05 PM ET	NMOSD + Q&A	Mark S. Freedman
1:25 PM ET	Q&A	Michael Nicolle, Mark S. Freedman, Vijay Ramaswamy

This program was developed by the CNSF and Alexion AstraZeneca Rare Disease and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.